Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
NPJ Breast Cancer|May 10, 2022
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancersXuan Liu, Zhongqi Ge, Fei Yang, et al.
Molecular Cancer Therapeutics|January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitorsFilip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancerStacy L Moulder, W Fraser Symmans, Daniel J Booser, et al.
Oncotarget|June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathwayJennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsFilip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Cancer|March 29, 2014
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancerRashmi K Murthy, Ankur Varma, Priyankana Mishra, et al.
Cancer|September 9, 2015
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapyAndrew J Bishop, Joe Ensor, Stacy L Moulder, et al.
Oncotarget|December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomesFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancersJennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Investigational New Drugs|October 13, 2018
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-βClinton Yam, Rashmi K Murthy, Gaiane M Rauch, et al.
Pageof 9